GENE ONLINE|News &
Opinion
Blog

Gilead Sciences
First and Only CAR T Therapy for Mantle Cell Lymphoma Gets FDA Nod
2020-07-30
BIO Digital 2020 Highlights: Challenges in Bringing New Cell and Gene Therapies to Market
2020-06-23
Dexamethasone Renews Hopes for a Life Saving COVID-19 Treatment
2020-06-20
Remdesivir Registers Middling Benefit in Patients with Moderate COVID-19
2020-06-01
Long-Acting Cabotegravir Injection Performs Better as an HIV PrEP than Daily Pills
2020-05-22
Potential Repurposed Drugs Currently in Evaluation for COVID-19
2020-05-01
COVID-19: Gilead’s Promising Remdesivir Data Jumps US Stocks, Hastens FDA’s Emergency Authorization Plans
2020-04-29
Gilead, Kite, and oNKo-innate Collaborate to Advance Cancer Immunotherapy Using NK Cells
2020-04-26
Remdesivir’s Early Trial Data Necessitates Guarded Optimism
2020-04-12
R&D
Gilead, Second Genome Partner to Explore Microbial Biomarkers
2020-04-08
Kite Pharma Licences Teneobio’s Antibody Platform to Fight Multiple Myeloma
2020-04-03
Daiichi Sankyo Seeks Yescarta Approval in Japan for Relapsed or Refractory B-cell Lymphoma
2020-04-01
Gilead Requests FDA to Rescind Remdesivir’s Orphan Drug Designation
2020-03-25
Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment
2020-03-24
Gilead’s Antiviral Drug, Epclusa gets FDA Nod for Pediatric Hepatitis C
2020-03-22
1 2 3 4
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!